{"nctId":"NCT01646671","briefTitle":"Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients","startDateStruct":{"date":"2012-07"},"conditions":["Severe Hypertension"],"count":35,"armGroups":[{"label":"LCZ696 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]},{"label":"LCZ696 400 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]},{"label":"LCZ696 400 mg plus other hypertension (HTN) medications","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]}],"interventions":[{"name":"LCZ696","otherNames":[]},{"name":"LCZ696","otherNames":[]},{"name":"LCZ696","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Satisfy office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at baseline\n\nExclusion Criteria:\n\n* Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg\n* History of angioedema, drug-related or otherwise, as reported by the patient\n* Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.\n* Patients have significant cardiovascular co-morbidities\n* Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.\n\nOther protocol defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths","description":"Adverse events, serious adverse events deaths were monitored from screening to week 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in msSBP and msDBP at Week 8","description":"Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP measurements were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.83","spread":"11.730"},{"groupId":"OG001","value":"-30.34","spread":"15.054"},{"groupId":"OG002","value":"-35.98","spread":"15.229"},{"groupId":"OG003","value":"-35.31","spread":"15.348"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.25","spread":"7.378"},{"groupId":"OG001","value":"-16.98","spread":"7.394"},{"groupId":"OG002","value":"-23.08","spread":"8.514"},{"groupId":"OG003","value":"-22.12","spread":"9.167"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Successful Blood Pressure (BP) Control in msSBP/msDBP at End of Study","description":"Successful BP control in patients with severe hypertension at the end of study treatment was defined as follows: msSBP/msDBP\\< 140/90 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"18.2","spread":null},{"groupId":"OG002","value":"47.6","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Successful msSBP Control at End of Study","description":"Successful msSBP control in patients with severe hypertension at the end of study treatment was defined as msSBP \\<140 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"45.5","spread":null},{"groupId":"OG002","value":"66.7","spread":null},{"groupId":"OG003","value":"62.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Successful msDBP Control at End of Study","description":"Successful msDBP control in patients with severe hypertension at the end of study treatment was defined as msDBP \\< 90 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"52.4","spread":null},{"groupId":"OG003","value":"48.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SBP Response at End of Study","description":"SBP response was defined as \\<140 mmHg or a reduction ≥ 20 mmHg from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"81.8","spread":null},{"groupId":"OG002","value":"85.7","spread":null},{"groupId":"OG003","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With DBP Response at End of Study","description":"DBP response was defined as \\<90 mmHg or a reduction ≥ 10 mmHg from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":35},"commonTop":["NASOPHARYNGITIS","BLOOD CREATINE PHOSPHOKINASE INCREASED","HYPERURICAEMIA"]}}}